Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Core Insights - Knight Therapeutics Inc. has submitted a New Drug Submission (NDS) for Qelbree® to Health Canada, marking a significant step in expanding its ADHD treatment portfolio [1][4] - Qelbree® is a novel nonstimulant medication for ADHD, already approved in the United States for patients aged 6 and older, with a growing market for non-stimulant ADHD treatments in Canada [2][4] Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [6] - The company operates under various subsidiaries in Latin America, including United Medical, Biotoscana Farma, and Laboratorio LKM [6] Product Development - Qelbree® is currently undergoing multiple clinical trials, including studies on its effectiveness in combination with psychostimulants and its impact on preschool-age children and adults with ADHD [3][4] - The first clinical trial reported positive topline results in September 2023, while a second trial for preschool-age children began in March 2024 [3] Market Insights - The Canadian market for non-stimulant ADHD products was valued at $83.5 million in 2023, with a 10% growth in prescriptions compared to 2022 and a compound annual growth rate (CAGR) of 11% over the past four years [4] - ADHD affects approximately 5-9% of children and adolescents and 3-5% of adults, indicating a significant ongoing medical need for effective treatment options [5]